They also demonstrated the potential of CXCR4 as a theranostic target in MM patients in a pilot study confirming the feasibility of CXCR4-directed radionuclide therapy using 177Lu or 90Y-CXCR4 ligand (pentixather) as a novel treatment approach for MM [39]. Here, CXCR4 is linked to Miyoshi myopathy.